Drug Profile
Research programme: arginase inhibitors - Molecure
Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator OncoArendi Therapeutics
- Developer Molecure
- Class Small molecules
- Mechanism of Action Arginase inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for research development in Unspecified in Poland (PO)
- 21 Feb 2020 OncoArendi has patents pending for arginase inhibitors in Poland, Europe, China, Canada, USA
- 21 Feb 2020 OncoArendi has patents pending for arginase inhibitors in Poland, Korea, Peru, USA, Australia, Mexico, Singapore, Canada, Brazil, Europe, China, Japan, Philippines, Israel, Chile and Colombia